Roundhill NVDA WeeklyPay ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.17 (market cap $119.10M), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 84.9× Roundhill NVDA WeeklyPay ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill NVDA WeeklyPay ETF for 50 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NVDW | XBI | |
|---|---|---|
Market Cap | $119.10M | $10.11B |
Volume | 44,838 | 12,903,266 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $52.33 | $169.55 |
52-Week Low | $31.88 | $104.99 |
Typical Hold Time | 50 Days | 38 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →